Pharmamarketeer

US FDA approves Roche’s Venclexta in combo with Gazyva to treat people with previously untreated CLL/SLL

Roche announced that the US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL)

Medhc-fases-banner
Advertentie(s)